1,25-二羟基维生素D3治疗特发性血小板增多症和骨髓纤维化
1,25-Dihydroxyvitamin D3 in the treatment of idiopathic thrombocythemia and myelofibrosis.
作者信息
Foa P, Maiolo A T, Cortellaro M, Ortolani S, Pogliani E, Deliliers G L, Iurlo A, Zocchi L, Gualdoni A, Polli E
机构信息
Istituto di Scienze Mediche, Padiglione Granelli, Università degli Studi, Milano, Italy.
出版信息
Haematologica. 1990 May-Jun;75(3):294-5.
The effect of treatment with 1,25-dihydroxyvitamin D3 administered at the dose of 1.50-3.00 ug/day for at least 12 months was evaluated in three patients with idiopathic myelofibrosis and in five patients with idiopathic thrombocythemia. This treatment did not cause any significant change in the hematological values or the clinical course of the myeloproliferative diseases in any of the patients. Based on these data, treatment with 1,25-dihydroxyvitamin D3 in non toxic doses seems to be of doubtful benefit in patients with these disorders.
对3例原发性骨髓纤维化患者和5例原发性血小板增多症患者评估了每天给予剂量为1.50 - 3.00微克的1,25 - 二羟维生素D3治疗至少12个月的效果。该治疗在任何患者中均未引起血液学值或骨髓增殖性疾病临床病程的任何显著变化。基于这些数据，无毒剂量的1,25 - 二羟维生素D3治疗对这些疾病患者的益处似乎存疑。
Zotero 插件